Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 18,398 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Clear all
Completed No phase listed Observational

Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant Women

NCT00017797
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2006 · Synced Oct 25, 2026, 11:44 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

APOL1 Genetic Testing in African Americans

NCT05656261
View directory record Official record
Conditions
Genetic Predisposition, Chronic Kidney Diseases, Nephropathy, APOL1 Associated Kidney Disease, Disparities
Interventions
Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys
Genetic
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Not applicable Interventional

Pivotal Test: WB001

NCT04576754
View directory record Official record
Conditions
Postpartum Depression
Interventions
WB001, Educational
Device
Lead sponsor
Woebot Health
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

NCT01628120
View directory record Official record
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
115
States / cities
Azusa, California • Bakersfield, California • Bellflower, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Phase 2 Interventional

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

NCT00091182
View directory record Official record
Conditions
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Recurrent Adrenocortical Carcinoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer
Interventions
oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 25, 2026, 11:44 AM EDT
Completed No phase listed Observational

Arteriovenous Fistula Tissue Bank for Pre- and Post-Fistula Placement Specimens

NCT00836862
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Biologic specimens
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 25, 2026, 11:44 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Estimating Blood Loss Using TritonTM in Vaginal Deliveries: A Validation Trial

NCT04277962
View directory record Official record
Conditions
Post Partum Hemorrhage, Blood Loss, Vaginal Bleeding, Vaginal Delivery
Interventions
Triton L and D system for estimation of blood loss at time of vaginal delivery
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

NCT05560646
View directory record Official record
Conditions
Endometriosis
Interventions
OG-6219, Placebo
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 25, 2026, 11:44 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

VR to Reduce Pain and Anxiety During GU Scans

NCT04251988
View directory record Official record
Conditions
Urologic Diseases, Urogenital Disease, Vesico-Ureteral Reflux
Interventions
Oculus Go VR
Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
5 Years to 21 Years
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Phase 1 Interventional

Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer

NCT03088527
View directory record Official record
Conditions
Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
RAD140
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
New Haven, Connecticut • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Phase 2 Interventional Results available

Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

NCT00420342
View directory record Official record
Conditions
Postmenopause, Hypertension, Pre-Hypertension
Interventions
Drospirenone/17ß-estradiol (Angeliq, BAY86-4891), SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Greenbrae, California • San Diego, California • Daytona Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Not applicable Interventional

MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery

NCT01691742
View directory record Official record
Conditions
Post Procedural Constipation
Interventions
MiraLax, Placebo, Rescue Laxative
Drug
Lead sponsor
Duke University
Other
Eligibility
19 Years and older · Female only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Phase 2 Interventional

Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy

NCT01442090
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Everolimus, GDC-0980
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Phase 4 Interventional Results available

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)

NCT00908310
View directory record Official record
Conditions
Chronic Kidney Disease, Renal Insufficiency
Interventions
Omniscan
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 25, 2026, 11:44 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer

NCT00126659
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
therapeutic conventional surgery, sorafenib tosylate, laboratory biomarker analysis
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 25, 2026, 11:44 AM EDT
Terminated Early Phase 1 Interventional

A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers

NCT01086696
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Renal Cancer, Adrenal Cancer
Interventions
FPAC
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Phase 1 Interventional

Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer

NCT02195973
View directory record Official record
Conditions
Recurrent Ovarian Cancer
Interventions
LDE225
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Phase 2 Interventional Results available

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

NCT00729586
View directory record Official record
Conditions
Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC1 Uterine Corpus Cancer, Stage IIIC2 Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
Laboratory Biomarker Analysis, Megestrol Acetate, Tamoxifen Citrate, Temsirolimus
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
108
States / cities
Burbank, California • Palo Alto, California • San Diego, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Not applicable Interventional

Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients

NCT00253383
View directory record Official record
Conditions
Cancer
Interventions
counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 25, 2026, 11:44 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women

NCT04327141
View directory record Official record
Conditions
Weight Loss, Gut Microbiome, Anti-Aging
Interventions
P-IF, HH
Behavioral
Lead sponsor
Skidmore College
Other
Eligibility
25 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Saratoga Springs, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 25, 2026, 11:44 AM EDT
Completed No phase listed Observational

WISE ARIC: Retinal Photography in Women With Chest Pain

NCT00187954
View directory record Official record
Conditions
Chest Pain
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Phase 4 Interventional Results available

MENOPUR® Versus FOLLISTIM®

NCT00802360
View directory record Official record
Conditions
Infertility
Interventions
Menotropin, Progestrone vaginal insert, follitropin beta, Progesterone in oil, Ganirelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Pasadena, California • San Diego, California • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 25, 2026, 11:44 AM EDT
Completed Phase 4 Interventional Results available

Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT

NCT00790062
View directory record Official record
Conditions
Uterine Atony, Postpartum Hemorrhage
Interventions
Oxytocin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Female only
Enrollment
1,798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 25, 2026, 11:44 AM EDT